Samuel Lynch DMD, DMSc

Dr. Samuel Lynch is a double-doctorate accomplished public and private company CEO, translational scientist, entrepreneur, and philanthropist. He has a Doctorate of Medical Sciences (DMSc) from Harvard Medical School, and specialty certification in periodontology from Harvard School of Dental Medicine. He has over 250 patents and publications and has founded and led several medical device and biotechnology companies. He is the inventor or was instrumental in the development of many of the world's leading regenerative medicine brands, including Ariessence pure PDGF+, Augment Bone Graft, Augment Injectable Bone Graft, GEM 21S, BioOss, and BioGide.

He is the founder and CEO of Lynch Regenerative Medicine (LRM), and previously founded and sold Lynch Biologics and BioMimetic Therapeutics, which he grew into a publicly-traded company on Nasdaq [BMTI], and sold in 2013 for approximately $400 million. LRM is focused on developing regenerative and rejuvenative solutions for skin disorders, deficiencies, and aging. In recognition of these achievements, he has received numerous awards and honors, including the Entrepreneur of the Year award from the Southeast Medical Device Association, Harvard Alumnus of the Year, and Southern Illinois Alumnus of the Year, to name a few.

He also served for nearly 8 years on the governing Board of Directors of Vanderbilt University Medical Center, a top 15 medical center in the United States with approximately 30,000 employees and $7 billion in annual revenues, where he has chaired both the Audit & Compliance Committee and the Compensation & Leadership Development Committee. He also serves as the Chairman of the Life Sciences Tennessee Foundation, a nonprofit he and his wife Leslie started in 2007 to promote K-12 STEM education.